Indeed, pre-clinical and clinical studies have shown that progressive disease in VEGF inhibitor-treated cancer can be mediated by FGF2 and SDF-1α [6, 7]; two of the multiple angiogenic cytokines that are critically dependent on heparan sulfate (HS). Here, FGF2 is linked to cancer.